Dear Doctor - Participate in the Survey on epilepsy " A new survey has found that nearly one in three people with epilepsy have experienced at least one seizure in the past year. The findings, from the Epilepsy Foundation's 2020 National Survey of Epilepsy Attitudes and Experiences, also reveal that half of all respondents worry about having a seizure in public."These survey results underscore the urgent need for improved access to care and treatments for people living with epilepsy," said Philip Gattone, CEO of the Epilepsy Foundation. "It is unacceptable that so many people with this condition are still facing challenges in getting the help they need."The survey, which was conducted online between February and March 2020, received more than 4,500 responses from people with epilepsy and their caregivers. Among other things, it found that:- 24% of respondents said they had not seen a doctor or other healthcare provider in the past year specifically for their epilepsy;- 36% said they have not been able to get all of the medication they need; and - 54% reported experiencing at least one seizure in the past year. Participate in Surveys "
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
Even when they are not paying attention, children are still learning.
4.
The Benefits of Exercise for Substance Use Disorders.
5.
The top three drugs for multiple myeloma treatment upfront are four.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
5.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation